Current Trends in Liquid Biopsy Technology for Early Diagnosis of Metastatic Renal Cell Carcinoma
10.22465/kjuo.2022.20.4.223
- Author:
Jeong Yoon SUH
1
;
Se Jung MAENG
;
Mirinae KIM
;
Su Jeong KANG
;
Young Wook CHOI
;
In Ho CHANG
Author Information
1. Department of Medicine, Chung-Ang University College of Medicine, Seoul, Korea
- Publication Type:Review Article
- From:Korean Journal of Urological Oncology
2022;20(4):223-234
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Clear cell renal cell carcinoma (ccRCC) is a disease with a wide variety of clinical progressions such as the rate of disease progression or the degree of metastasis. About 30% of ccRCC patients suffer from metastatic diseases, and about 30% develop metastasis after diagnosis. In the case of metastatic RCC, early prediction of the disease is important because of the poor prognosis, but ccRCC-specific molecular markers for clinical use are not available yet. As an alternative, liquid biopsy, which can find molecules released from tumor tissues in circulating blood and obtain information on metastatic dissemination and recurrence of ccRCC, is emerging. In this article, we will introduce molecules such as cell free DNA, cell free RNA, protein, and exosomes available as circulating biomarkers for liquid biopsy. We will also introduce some promising technologies that can compensate for the limitations of liquid biopsy.
